Creutzfeldt Jakob Disease News and Research

RSS

Creutzfeldt–Jakob disease or CJD (sometimes incorrectly referred to as mad cow disease) is a degenerative neurological disorder (brain disease) that is incurable and invariably fatal. It is the most common among the types of transmissible spongiform encephalopathy found in humans.

Disruption of copper regulation key to prion diseases

An investigation of a rare, inherited form of Creutzfeldt-Jakob disease suggests that disrupted regulation of copper ions in the brain may be a key factor in this and other prion diseases.

16 Apr 2009

Imbalance of iron homeostasis involved in prion disease-associated neuronal demise

Imbalance of iron homeostasis is a common feature of prion disease-affected human, mouse, and hamster brains, according to a new study by Dr. Neena Singh and colleagues at Case Western Reserve University School of Medicine, alongside collaborators from Creighton University.

15 Mar 2009

Antibody key to treating variant CJD

Scientists at the University of Liverpool have determined the atomic structure of the 'binding' between a brain protein and an antibody that could be key to treating patients with diseases such as variant CJD.

4 Mar 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Scientists create infectious prion disease in mouse model

A worldwide group of scientists has created an infectious prion disease in a mouse model, in a step that may help unravel the mystery of this progressive disease that affects the nervous system in humans and animals.

8 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

Mouse model of prion disease mimics diverse symptoms of human disorder

A comprehensive mouse model of inherited prion disease exhibits cognitive, motor, and neurophysiological deficits that bear a striking resemblance to the symptoms experienced by patients with the human version of "mad cow disease," Creutzfeldt-Jakob disease (CJD).

26 Nov 2008

New molecules with many branches will help unleash potential of nanotechnology

Materials science and the pharmaceutical industry could soon be revolutionized by emerging nanotechnologies based on designer molecules with long complex tree-and branch structures. Such molecules offer almost limitless scope for design of bespoke compounds for specific applications in disease therapy, for novel materials such as resins, as well as electronic displays, and energy storage. Almost every field involving design and synthesis of chemical compounds will be transformed by the arrival of technologies allowing nanoscale design of these branched molecules, known as hyperbranched polymers.

26 Oct 2008

Worries over test for mad cow disease

A new test to screen blood for the incurable human form of mad cow disease could be available within 18 months, but it has raised concerns.

21 Oct 2008

University of California, San Francisco embraces web 2.0 for health information

YouTube and The University of California, San Francisco (UCSF) today launched a comprehensive Internet video channel dedicated to the improved understanding of incurable neurodegenerative brain diseases.

16 Jun 2008

Intracellular antibody mops up mutant protein in Huntington's disease model

Scientists have created a tool for mopping up the clumps of mutant protein that drive neurodegeneration in Huntington's disease. Emory University researchers engineered a virus to make an intracellular antibody or "intrabody" against huntingtin, the protein whose mutant forms poison the brain cells of people with Huntington's.

26 May 2008

FDA issues regulation on animal feeds with added safeguards against BSE

The U.S. Food and Drug Administration today issued a final regulation barring certain cattle materials from all animal feed, including pet food. The final rule further protects animals and consumers against bovine spongiform encephalopathy (BSE, also known as "mad cow disease").

23 Apr 2008

An atomic view of protein behind hereditary cerebral amyloid angiopathy

For the first time, researchers have peered deeply at the atomic level into the protein that causes hereditary cerebral amyloid angiopathy (CAA) -- a disease thought to cause stroke and dementia.

22 Apr 2008

Special filter quickly and effectively removes deadly vCJD protein from blood

Amid concern that recipients of certain blood transfusions may risk infection with a deadly protein responsible for the human form of mad cow disease, researchers in Canada now report development of a special filter that quickly and effectively removes the protein from blood.

9 Apr 2008